Page last updated: 2024-10-22

alpha-methyltyrosine methyl ester and Parkinson Disease, Secondary

alpha-methyltyrosine methyl ester has been researched along with Parkinson Disease, Secondary in 1 studies

alpha-methyltyrosine methyl ester: RN given refers to parent cpd

Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sundström, E1
Fredriksson, A1
Archer, T1

Other Studies

1 other study available for alpha-methyltyrosine methyl ester and Parkinson Disease, Secondary

ArticleYear
Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
    Brain research, 1990, Oct-01, Volume: 528, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Body Weight; Corpus Striatum; Di

1990